Analysts Offer Predictions for C4 Therapeutics FY2029 Earnings

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Equities research analysts at Brookline Capital Management issued their FY2029 earnings per share estimates for shares of C4 Therapeutics in a report released on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will earn $28.08 per share for the year. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.52) per share.

Other research analysts have also issued reports about the stock. Stephens initiated coverage on shares of C4 Therapeutics in a research note on Monday, November 18th. They issued an “equal weight” rating and a $4.00 price target on the stock. Wells Fargo & Company raised C4 Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $8.00 to $12.00 in a research note on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.67.

C4 Therapeutics Stock Performance

NASDAQ:CCCC opened at $3.84 on Wednesday. The company has a fifty day moving average of $4.44 and a two-hundred day moving average of $5.38. C4 Therapeutics has a fifty-two week low of $3.43 and a fifty-two week high of $11.88. The stock has a market capitalization of $271.06 million, a PE ratio of -2.26 and a beta of 2.96.

C4 Therapeutics (NASDAQ:CCCC) last posted its earnings results on Thursday, October 31st. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. The firm had revenue of $15.36 million for the quarter, compared to analysts’ expectations of $5.95 million. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%.

Institutional Trading of C4 Therapeutics

Several hedge funds have recently made changes to their positions in the company. Lynx1 Capital Management LP lifted its holdings in C4 Therapeutics by 89.3% in the second quarter. Lynx1 Capital Management LP now owns 6,880,527 shares of the company’s stock valued at $31,788,000 after acquiring an additional 3,245,865 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in shares of C4 Therapeutics by 331.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,201,848 shares of the company’s stock valued at $6,851,000 after purchasing an additional 923,268 shares during the last quarter. Wasatch Advisors LP lifted its stake in shares of C4 Therapeutics by 17.1% in the 3rd quarter. Wasatch Advisors LP now owns 5,677,368 shares of the company’s stock valued at $32,361,000 after purchasing an additional 830,218 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of C4 Therapeutics during the 2nd quarter worth about $881,000. Finally, FMR LLC increased its position in shares of C4 Therapeutics by 687.0% during the 3rd quarter. FMR LLC now owns 185,941 shares of the company’s stock worth $1,060,000 after purchasing an additional 162,314 shares during the last quarter. Hedge funds and other institutional investors own 78.81% of the company’s stock.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.